News

Canadians benefitting from substantially lower generic drug prices

August 14, 2019

Latest agreement between public payers and the Canadian generic industry closes gap with international prices


Statement by PMPRB Chairperson on changes to the Patented Medicines Regulations

August 9, 2019

Patented Medicine Prices Review Board (PMPRB) Chairperson Dr. Mitchell Levine made the following statement regarding Health Canada’s final amendments to the Patented Medicines Regulations.


New PMPRB Report examines most promising medicines currently in clinical trials worldwide

May 30, 2019

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2018 edition of Meds Pipeline Monitor.


New Drug Landscape Dominated by High-cost Medicines

February 19, 2019

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2017 edition of Meds Entry Watch, an annual publication that provides the latest information on new medicines entering Canadian and international markets.


Patented Medicine Prices Review Board issues a Notice of Hearing for allegations of excessive pricing of Procysbi

January 16, 2019

The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.


PAGE 1 - 2 - 3 - 4 - 5  NEXT 25  LAST 5 
Date modified: